ASCP Applauds Introduction of the Ensuring Community Access to Pharmacist Services Act (ECAPS)
Reintroduced Bill Takes Step Toward Pharmacy Provider Status
ALEXANDRIA, VIRGINIA / ACCESS Newswire / May 2, 2025 / Today, The American Society of Consultant Pharmacists (ASCP) expressed its strong support for the introduction of the Ensuring Community Access to Pharmacist Services Act (ECAPS) (H.R. 3164) a transformative bill that will formally recognize pharmacists as healthcare providers under Medicare and expand access to essential pharmacy services. This bipartisan legislation, introduced by Representative Adrian Smith (R-NE), will allow pharmacists to bill Medicare Part B for testing, treatment, and immunization services related to infectious diseases such as influenza, COVID-19, strep throat, and respiratory syncytial virus (RSV).
ECAPS is a monumental step forward for the pharmacy profession. By enabling pharmacists to provide these services under Medicare, the bill will increase access to timely, cost-effective care, especially for our older adults who rely heavily on LTC pharmacies for their healthcare needs.
'ASCP has long advocated for expanded roles for pharmacists, especially in long-term care settings, and the introduction of ECAPS marks a major milestone in our continued fight to recognize the vital contributions of pharmacists in patient care,' said Chad Worz, PharmD, ASCP's Chief Executive.
The bill also proposes a lower reimbursement rate (80% of the Physician Fee Schedule) for pharmacists, offering a cost-effective alternative to physicians. 'Throughout the COVID pandemic, pharmacists were essential to care providing testing, treatment and more than 2/3s of all vaccine administrations. Clearly, pharmacists are key and trusted partners in team-based care,' said Worz. 'ECAPS not only increases access to high-quality care for patients but also allows Medicare to operate more efficiently. It's a win-win-win for patients, providers and the government.'
Notably, the bill respects state-level scope of practice laws, ensuring that pharmacists only provide services authorized within their state's regulations.
As the bill moves through Congress, ASCP calls on lawmakers to support this critical legislation, empowering pharmacists to continue improving public health and expand access to essential pharmacy services nationwide.
About ASCP:
The American Society of Consultant Pharmacists (ASCP) is the only international professional society devoted to optimal medication management and improved health outcomes for all older persons. ASCP's members manage and improve drug therapy and improve the quality of life of geriatric patients and other individuals residing in a variety of environments, including nursing facilities, sub-acute care and assisted living facilities, psychiatric hospitals, hospice programs, and home and community-based care.
###
Contact InformationMelissa Blacketer Senior Director of Communications 703-739.1311
SOURCE: ASCP
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
28 minutes ago
- Business Wire
Simplify Healthcare's Benefits1™.Medicare Drives Over 30% of Nationwide PBP Submissions to CMS, Marking Over 7 Years as a Trusted Industry Leader
AURORA, Ill.--(BUSINESS WIRE)-- Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA) Plan Benefit Package (PBP) submissions to the Centers for Medicare & Medicaid Services (CMS) this year. This milestone highlights the platform's transformative impact on benefit plan management and its integral role in supporting Payers across the nation. Benefits1™.Medicare continues to be the industry leader, enabling large-scale CMS bid submissions successfully for over 7 years, while also importing data seamlessly from the CMS-PBP software. Designed to handle the complexities of bid submission and accessible immediately (benefit updates can be started at any time independent of HPMS releases), the platform continues to set the standard for speed, accuracy, and compliance in PBP submissions with its seamless integration, robust reporting, global data updates, secure user roles, workflow automation and audit tracking capabilities. 'Our customers relied on Benefits1™.Medicare to streamline over 30% of nationwide PBP submissions—proof of the trust we've earned and the efficiency our platform delivers year after year.' — Ramesh Padri, VP of Product Delivery at Simplify Healthcare. 'Managing the full Medicare Advantage lifecycle—from bids to digital delivery—makes Benefits1™.Medicare truly stand out in helping Payers drive value and improve member experiences.' — Tasneem Chital, VP of Government Markets at Simplify Healthcare. Industry Leadership Through Customer Focus As healthcare organizations face increasing operational and regulatory challenges, Benefits1™.Medicare offers an effective solution that simplifies workflows while driving greater organizational efficiency. 'This milestone reflects our long-standing commitment of partnering with health plans to successfully manage bid submissions. We bring the full stack partnership experience — people, thought leaders, product, and technology — towards delivering a superior bid submission experience for our customers.' — Nirnay Patel, EVP & GM of Benefits1™ at Simplify Healthcare. About Simplify Healthcare Simplify Healthcare powers connected benefits and provider journeys for Payers through a scalable, enterprise-grade, secure, compliant, and configurable cloud-based software platform — Simplify Health Cloud™. We offer highly scalable, technology-centered document and translation management services to Payers through Simplify Docs™. We also empower industries with AI-native SaaS solutions designed to build and deploy digital solutions faster, better, and with embedded AI through SimplifyX™.
Yahoo
29 minutes ago
- Yahoo
Simplify Healthcare's Benefits1™.Medicare Drives Over 30% of Nationwide PBP Submissions to CMS, Marking Over 7 Years as a Trusted Industry Leader
AURORA, Ill., June 06, 2025--(BUSINESS WIRE)--Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA) Plan Benefit Package (PBP) submissions to the Centers for Medicare & Medicaid Services (CMS) this year. This milestone highlights the platform's transformative impact on benefit plan management and its integral role in supporting Payers across the nation. Benefits1™.Medicare continues to be the industry leader, enabling large-scale CMS bid submissions successfully for over 7 years, while also importing data seamlessly from the CMS-PBP software. Designed to handle the complexities of bid submission and accessible immediately (benefit updates can be started at any time independent of HPMS releases), the platform continues to set the standard for speed, accuracy, and compliance in PBP submissions with its seamless integration, robust reporting, global data updates, secure user roles, workflow automation and audit tracking capabilities. "Our customers relied on Benefits1™.Medicare to streamline over 30% of nationwide PBP submissions—proof of the trust we've earned and the efficiency our platform delivers year after year." — Ramesh Padri, VP of Product Delivery at Simplify Healthcare. "Managing the full Medicare Advantage lifecycle—from bids to digital delivery—makes Benefits1™.Medicare truly stand out in helping Payers drive value and improve member experiences." — Tasneem Chital, VP of Government Markets at Simplify Healthcare. Industry Leadership Through Customer Focus As healthcare organizations face increasing operational and regulatory challenges, Benefits1™.Medicare offers an effective solution that simplifies workflows while driving greater organizational efficiency. "This milestone reflects our long-standing commitment of partnering with health plans to successfully manage bid submissions. We bring the full stack partnership experience — people, thought leaders, product, and technology— towards delivering a superior bid submission experience for our customers." — Nirnay Patel, EVP & GM of Benefits1™ at Simplify Healthcare. About Simplify Healthcare Simplify Healthcare powers connected benefits and provider journeys for Payers through a scalable, enterprise-grade, secure, compliant, and configurable cloud-based software platform — Simplify Health Cloud™. We offer highly scalable, technology-centered document and translation management services to Payers through Simplify Docs™. We also empower industries with AI-native SaaS solutions designed to build and deploy digital solutions faster, better, and with embedded AI through SimplifyX™. View source version on Contacts Simplify HealthcarePhone: (844) 720-6678Email: info@ Sign in to access your portfolio
Indianapolis Star
2 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
